Article | Published:

Unilateral ex vivo gene therapy by GDNF in epileptic rats

Gene Therapyvolume 26pages6574 (2019) | Download Citation


Temporal lobe epilepsy (TLE) is the most common type of epilepsy in adults. This neurological disorder is characterized by focal seizures originating in the temporal lobe, often with secondary generalization. A variety of pharmacological treatments exist for patients suffering from focal seizures, but systemically administered drugs offer only symptomatic relief and frequently cause unwanted side effects. Moreover, available drugs are ineffective in one third of the epilepsy patients. Thus, developing more targeted and effective treatment strategies for focal seizures, originating from, e.g., the temporal lobe, is highly warranted. In order to deliver potential anti-epileptic agents directly into the seizure focus we used encapsulated cell biodelivery (ECB), a specific type of ex vivo gene therapy. Specifically, we asked whether unilateral delivery of glial cell line-derived neurotrophic factor (GDNF), exclusively into the epileptic focus, would suppress already established spontaneous recurrent seizures (SRS) in rats. Our results show that GDNF delivered by ECB devices unilaterally into the seizure focus in the hippocampus effectively decreases the number of SRS in epileptic rats. Thus, our study demonstrates that focal unilateral delivery of neurotrophic factors, such as GDNF, using ex vivo gene therapy based on ECB devices could be an effective anti-epileptic strategy providing a bases for the development of a novel, alternative, treatment for focal epilepsies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Lévesque M, Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev. 2013;37:2887–99.

  2. 2.

    Yilmazer-Hanke DM, Wolf HK, Schramm J, Elger CE, Wiestler OD, Blümcke I. Subregional pathology of the amygdala complex and entorhinal region in surgical specimens from patients with pharmacoresistant temporal lobe epilepsy. J Neuropathol Exp Neurol. 2000;59:907–20.

  3. 3.

    Kanter-Schlifke I, Fjord-Larsen L, Kusk P, Ängehagen M, Wahlberg L, Kokaia M. GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus. Exp Neurol. 2009;216:413–9.

  4. 4.

    Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006;367:1087–100.

  5. 5.

    Engel J, McDermott M, Wiebe S, Langfitt JT, Stern JM, Dewar S. Early surgical therapy for drug-resistant temporal lobe epilepsy. J Am Vet Med Assoc. 2012;307:922–30.

  6. 6.

    Eriksdotter-Jönhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N, et al. Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33:18–28.

  7. 7.

    Tornøe J, Torp M, Jørgensen JR, Emerich DF, Thanos C, Bintz B, et al. Encapsulated cell-based biodelivery of Meteorin is neuroprotective in the quinolinic acid rat model of neurodegenerative disease. Restor Neurol Neurosci. 2012;30:225–36.

  8. 8.

    Nikitidou L, Torp M, Fjord-Larsen L, Kusk P, Wahlberg LU, Kokaia M. Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus. Epilepsia. 2014;55:167–74.

  9. 9.

    Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Sci (80-). 1993;260:1130 LP–1132.

  10. 10.

    Springer JE, Mu X, Bergmann LW, Trojanowski JQ. Expression of GDNF mRNA in Rat and Human Nervous Tissue. Exp Neurol. 1994;p.127:167–70.

  11. 11.

    Pochon A-M,N, Menoud A, Tseng JL, Zurn AD, Aebischer P. Neuronal GDNF expression in the adult rat nervous system identified bu in situ hybridisation. Eur J Neurosci. 1997;9:463–71.

  12. 12.

    Burazin TCD, Gundlach AL. Localization of GDNF/neurturin receptor (c-ret, GFRα-1 and α-2) mRNAs in postnatal rat brain: Differential regional and temporal expression in hippocampus, cortex and cerebellum. Mol Brain Res. 1999;73:151–71.

  13. 13.

    Martin D, Miller G, Rosendahl M, Russell DA. Potent inhibitory effects of glial derived neurotrophic factor against kainic acid mediated seizures in the rat. Brain Res. 1995;683:172–8.

  14. 14.

    Yoo YM, Lee CJ, Lee U, Kim YJ. Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus. Exp Neurol. 2006;200:407–17.

  15. 15.

    Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther. 2007;15:1106–13.

  16. 16.

    Nikitidou Ledri L, Melin E, Christiansen SH, Gøtzsche CR, Cifra A, Woldbye DPD, et al. Translational approach for gene therapy in epilepsy: Model system and unilateral overexpression of neuropeptide Y and Y2 receptors. Neurobiol Dis. 2016;86:52–61.

  17. 17.

    Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60:69–73.

  18. 18.

    Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson’s disease? Exp Neurol. 2008;209:82–8.

  19. 19.

    Falcicchia C, Paolone G, Emerich DF, Lovisari F, Bell WJ, Fradet T, et al. Seizure-suppressant and neuroprotective effects of encapsulated BDNF-producing cells in a rat model of temporal lobe epilepsy. Mol Ther Methods Clin Dev. 2018;9:211–24.

  20. 20.

    Vezzani A, Lang B, Aronica E. Immunity and inflammation in epilepsy. Cold Spring Harb Perspect Med. 2016;6:a022699.

  21. 21.

    Rocha SM, Cristovão AC, Campos FL, Fonseca CP, Baltazar G. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis. 2012;47:407–15.

  22. 22.

    Weissberg I, Wood L, Kamintsky L, Vazquez O, Milikovsky DZ, Alexander A, et al. Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction. Neurobiol Dis. 2015;78:115–25.

  23. 23.

    Shimizu F, Sano Y, Saito K, Abe MA, Maeda T, Haruki H, et al. Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier. Neurochem Res. 2012;37:401–9.

  24. 24.

    Pozas E, Ibáñez CF. GDNF and GFRα1 promote differentiation and tangential migration of cortical GABAergic neurons. Neuron. 2005;45:701–13.

  25. 25.

    Paratcha G, Ibáñez CF, Ledda F. GDNF is a chemoattractant factor for neuronal precursor cells in the rostral migratory stream. Mol Cell Neurosci. 2006;31:505–14.

  26. 26.

    Perrinjaquet M, Sjostrand D, Moliner A, Zechel S, Lamballe F, Maina F, et al. MET signaling in GABAergic neuronal precursors of the medial ganglionic eminence restricts GDNF activity in cells that express GFR 1 and a new transmembrane receptor partner. J Cell Sci. 2011;124:2797–805.

  27. 27.

    Bespalov MM, Sidorova YA, Tumova S, Ahonen-Bishopp A, Magalhães AC, Kulesskiy E, et al. Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J Cell Biol. 2011;192:153–69.

  28. 28.

    Canty AJ, Dietze J, Harvey M, Enomoto H, Milbrandt J, Ibanez CF. Regionalized loss of parvalbumin interneurons in the cerebral cortex of mice with deficits in GFR 1 signaling. J Neurosci. 2009;29:10695–705.

  29. 29.

    Ledda F, Paratcha G, Sandoval-Guzmán T, Ibáñez CF. GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nat Neurosci. 2007;10:293–300.

  30. 30.

    Magnusson JP, Goritz C, Tatarishvili J, Dias DO, Smith EMK, Lindvall O, et al. A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse. Science. 2014;346:237–41.

  31. 31.

    Marks C, Belluscio L, Ibáñez CF. Critical role of GFRα1 in the development and function of the main olfactory system. J Neurosci. 2012;32:17306–20.

  32. 32.

    Fjord-Larsen L, Kusk P, Emerich DF, Thanos C, Torp M, Bintz B, et al. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. Gene Ther. 2012;19:1010–7.

  33. 33.

    Fjord-Larsen L, Kusk P, Tornøe J, Juliusson B, Torp M, Bjarkam CR, et al. Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the göttingen minipig basal forebrain. Mol Ther. 2010;18:2164–72.

  34. 34.

    Racine RJ. Modification of seizure activity by electrical stimulation: I. after-discharge threshold. Electroencephalogr Clin Neurophysiol. 1972;32:269–79.

  35. 35.

    Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: An open source platform for biological image analysis. Nat Methods. 2012;9:676–82.

Download references


We thank Susanne Jonsson and Nora Pernaa for performing the immunohistochemistry.


This work received financial support by the European Commission, FP7-PEOPLE-2011-IAPP, project 285827.

Author information

Author notes

  1. These authors contributed equally: Avtandil Nanobashvili and Esbjörn Melin.


  1. NsGene A/S, Ballerup, Denmark

    • Avtandil Nanobashvili
    •  & Jens Tornøe
  2. Epilepsy Centre, Department of Clinical Sciences, Lund University Hospital, Lund, Sweden

    • Esbjörn Melin
    •  & Merab Kokaia
  3. NsGene, Inc, Providence, RI, USA

    • Dwaine Emerich
    •  & Lars Wahlberg
  4. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    • Michele Simonato
  5. Division of Neuroscience, University Vita-Salute San Raffaele, Milan, Italy

    • Michele Simonato


  1. Search for Avtandil Nanobashvili in:

  2. Search for Esbjörn Melin in:

  3. Search for Dwaine Emerich in:

  4. Search for Jens Tornøe in:

  5. Search for Michele Simonato in:

  6. Search for Lars Wahlberg in:

  7. Search for Merab Kokaia in:

Conflict of interest

LW is the scientific founder of NsGene A/S, and an employee of the company with minor share ownership. The remaining authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Merab Kokaia.

About this article

Publication history





Issue Date